A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Cemiplimab (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 09 Sep 2024 New trial record